welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
start date: September 2012
estimated completion: August 2016
size / enrollment: 53
The purpose of this tissue bank is to collect blood and skin samples from participants who are diagnosed with Duchenne muscular dystrophy (DMD) and carry one of nine specific changes in the dystrophin gene. The specific dystrophin changes that we are interested in studying are those that would work with exon-skipping therapies in patients with DMD, specifically deletions of the follow exons: 10-52, 13-50, 29-50, 43-52, 44, 43-50, 45-50, 45-52, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-60, 47-50, 47-52, 48-50, 49-50, 50, 52, 52-63, 48-52, 49-52, 50-52.
These blood and skin samples will be held in a tissue bank at Carolinas Medical Center for future DMD research.
- Tissue Collection [ Time Frame: 1 day ]
Collection of blood, skin and optional muscle samples
• Age 4 and above
• Diagnosis of DMD with a confirmed out-of-frame dystrophin gene deletions that could be corrected by skipping exon 45, 51, or 53 based on past genetic testing.
exclusion criteria: Investigator assessment of inability to comply with blood and skin sample collection
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
Sarepta Receives Negative CHMP Re-examination Opinion for EteplirsenSarepta Therapeutics, Inc., a commercial...
A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...